Sudeep Pharma Q1FY27 profit rises 30%; earnings call details growth drivers
NiveshIQ
NSE: SUDEEPPHRM · Healthcare
Sudeep Pharma Ltd.
₹1,202.80▼ ₹10.70 (-0.88%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on SUDEEPPHRM. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Sudeep Pharma Ltd.
Sudeep Pharma Limited, headquartered in Vadodara, specializes in manufacturing excipients and specialty ingredients for pharmaceutical, food, and nutrition markets across India, the US, and internationally. Its product portfolio includes mineral salts such as iron, calcium, sodium, zinc, copper, magnesium, manganese, potassium, picolinates, and simethicone, as well as micronutrient premixes, liposomal and encapsulated ingredients, spray‑dried formats, and granulated products for sports nutrition, medical and clinical nutrition, infant nutrition, beverages, fortified staples, functional foods, and dairy. In FY26, the company achieved a 27.9% revenue growth to ₹642.3 crore, with net income of ₹183 crore, reflecting strong demand in both domestic and export segments. Recent market activity sh
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹454.67 Cr +6.70% | ₹497.41 Cr +9.40% | ₹642.26 Cr +29.10% |
| EBITDA Margin | 41.11% | 39.82% | 39.00% |
| Net Profit | ₹133.19 Cr +113.70% | ₹138.69 Cr +4.10% | ₹174.28 Cr +25.70% |
| EPS | ₹11.79 | ₹12.28 | ₹15.50 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Pharma sector stocks decline today, September 11: Sudeep Pharma falls 4.58%, Orchid Pharma down 3.56%, Alembic Pharma drops 1.43
Pharma sector stocks today, September 10: Sudeep Pharma falls 5%, Alembic Pharma down 2%; Alembic Pharma up 1.58%
🔒
+ 3 more stories about Sudeep Pharma Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹158 Cr, PAT ₹41 Cr, EPS ₹3.59, EBITDA margin 38.1%. Growth context: revenue QoQ -13.2%, PAT QoQ -16.4%. Street verdict: inline, revenue surprise -6.8%, PAT surprise -0.2%.
Management commentary points to product launches, approvals, and therapy-mix improvement as the primary near-term growth...
FY26 (last completed FY): revenue ₹642 Cr, PAT ₹174 Cr, EBITDA margin 39.0%, EPS ₹15.50. Year-on-year: revenue YoY +29.1...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for SUDEEPPHRM
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track SUDEEPPHRM alongside your other holdings
Unlock full SUDEEPPHRM research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Sudeep Pharma Ltd.?
NiveshIQ detects active intelligence signals for Sudeep Pharma Ltd. (SUDEEPPHRM) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Sudeep Pharma Ltd.?
Sudeep Pharma Ltd. operates in the Healthcare sector with a market capitalisation of ₹745,460.9L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.